Literature DB >> 11130770

Altered frequency of a promoter polymorphism of the kinin B2 receptor gene in hypertensive African-Americans.

J V Gainer1, N J Brown, M Bachvarova, L Bastien, I Maltais, F Marceau, D R Bachvarov.   

Abstract

Components of the kallikrein kinin system have been associated with the pathophysiology of hypertension in animal and human studies. In this study, we examined the distribution of four different polymorphisms of the kinin B1 and B2 receptor genes in a population of 120 normotensive and 77 hypertensive African-Americans. Allelic frequencies for three of the four polymorphisms were significantly different from those previously reported in Caucasian populations. Among the polymorphisms analyzed, a potentially functionally significant polymorphism in the core promoter of the kinin B2 receptor (C-58-->T transition) displayed an increased prevalence of the C-58 allele in the hypertensive patients as compared with the controls (0.75 v. 0.62, P = .009). Thus, this B2 receptor promoter polymorphism may represent a susceptibility marker for essential hypertension in African-Americans.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11130770     DOI: 10.1016/s0895-7061(00)01215-2

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  11 in total

1.  The risk of bradykinin B2 receptor-58T/C gene polymorphism on hypertension: a meta-analysis.

Authors:  Kaiping Luo; Wenling Kang; Gaosi Xu
Journal:  Int J Clin Exp Med       Date:  2015-11-15

2.  Association of the human bradykinin B2 receptor gene with chronic renal failure.

Authors:  Lucyna Jozwiak; Andrzej Drop; Kinga Buraczynska; Piotr Ksiazek; Piotr Mierzicki; Monika Buraczynska
Journal:  Mol Diagn       Date:  2004

3.  The role of the kallikrein-kinin system genes in the salt sensitivity of blood pressure: the GenSalt Study.

Authors:  Dongfeng Gu; Qi Zhao; Tanika N Kelly; James E Hixson; Dabeeru C Rao; Jie Cao; Jing Chen; Jianxin Li; Jichun Chen; Xu Ji; Dongsheng Hu; Xushan Wang; De-Pei Liu; Jiang He
Journal:  Am J Epidemiol       Date:  2012-10-01       Impact factor: 4.897

4.  High salt-induced hypertension in B2 knockout mice is corrected by the ETA antagonist, A127722.

Authors:  I Brochu; M Houde; L Desbiens; E Simard; F Gobeil; W Semaan; G Bkaily; P D'Orléans-Juste
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

Review 5.  Genetics of Human Primary Hypertension: Focus on Hormonal Mechanisms.

Authors:  Worapaka Manosroi; Gordon H Williams
Journal:  Endocr Rev       Date:  2019-06-01       Impact factor: 19.871

6.  Bradykinin type-2 receptor expression correlates with age and is subjected to transcriptional regulation.

Authors:  Inka Liesmaa; Naotaka Shiota; Jorma O Kokkonen; Petri T Kovanen; Ken A Lindstedt
Journal:  Int J Vasc Med       Date:  2011-10-03

Review 7.  A Novel Category of Anti-Hypertensive Drugs for Treating Salt-Sensitive Hypertension on the Basis of a New Development Concept.

Authors:  Makoto Katori; Masataka Majima
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-07

8.  Association between the CYP4A11 T8590C variant and essential hypertension: new data from Han Chinese and a meta-analysis.

Authors:  Hua-Cheng Yan; Jun-Hua Liu; Jian Li; Bao-Xia He; Liang Yang; Jian Qiu; Liang Li; Da-Peng Ding; Lei Shi; Shu-Jin Zhao
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

9.  Association of B2 receptor polymorphisms and ACE activity with ACE inhibitor-induced angioedema in black and mixed-race South Africans.

Authors:  Retsilisitsoe R Moholisa; Brian R Rayner; E Patricia Owen; Sylva L U Schwager; Joalice S Stark; Motassim Badri; Clint L Cupido; Edward D Sturrock
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-04-11       Impact factor: 3.738

10.  Bradykinin β2 receptor -58T/C gene polymorphism and essential hypertension: a meta-analysis.

Authors:  Yan-yan Li; Hui Zhang; Jian Xu; Yun Qian; Xin-zheng Lu; Bing Yang; Minglong Chen; Zhi-jian Yang; Ke-jiang Cao
Journal:  PLoS One       Date:  2012-08-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.